Regulation and governance of multinational drug trials in stroke: barriers and possibilities.

Abstract

Over the last 10 years, there has been stagnation in the number of multinational drug trials in stroke in Europe. One important cause of this is probably the increased burden of laws and regulations that came with the European Union Clinical Trials Directive. The main objective of research regulation and governance should be to protect research participants… (More)
DOI: 10.1111/ijs.12427

Topics

Cite this paper

@article{Berge2015RegulationAG, title={Regulation and governance of multinational drug trials in stroke: barriers and possibilities.}, author={Eivind Berge and Gary A. Ford and Philip M Bath and Christian Stapf and H. Bart van der Worp and Jacques Demotes and Joseph Broderick and Rustam Al-Shahi Salman and Kennedy R. Lees}, journal={International journal of stroke : official journal of the International Stroke Society}, year={2015}, volume={10 3}, pages={425-8} }